ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
DealStreetAsia

Singapore Hummingbird to start COVID antibody therapy trial

SK-backed startup receives approval from local authorities

 A nurse cares for a COVID-19 patient in the intensive care unit at King Chulalongkorn Memorial Hospital in Bangkok on April 23, 2020.   © Reuters

SINGAPORE -- Cancer antibody developer Hummingbird Bioscience has received approval from Singapore health authorities to start a clinical trial for COVID-19 antibody therapy.

Early trials are ongoing while a Phase 3 trial is scheduled for the end of the year. The latest trial will study the safety and efficacy of the experimental treatment HMBD-115, the company said.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more